Comparative Pharmacology
Head-to-head clinical analysis: QVAR REDIHALER versus VANCERIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QVAR REDIHALER versus VANCERIL.
QVAR REDIHALER vs VANCERIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beclomethasone dipropionate is a prodrug that is hydrolyzed by esterases to the active metabolite beclomethasone-17-monopropionate (17-BMP). 17-BMP is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression involved in inflammatory pathways, including inhibition of pro-inflammatory cytokines, reduction of eosinophil survival and migration, and suppression of mast cell mediators.
Beclomethasone dipropionate is a corticosteroid that exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine production in the airways.
Inhalation: 40-80 mcg twice daily; maximum 320 mcg twice daily.
2 inhalations (84 mcg) 3-4 times daily via oral inhalation.
None Documented
None Documented
1.5-2.0 hours (terminal half-life) after inhalation; supports twice-daily dosing.
Terminal elimination half-life is approximately 2.8 hours in adults; prolonged in patients with hepatic impairment.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (~64%) and urine (~12%).
Primarily hepatic metabolism; <10% excreted unchanged in urine, <5% in feces.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid